NASDAQ:NBTX Nanobiotix (NBTX) Stock Price, News & Analysis $5.30 -0.06 (-1.12%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.04▼$5.3750-Day Range$4.68▼$6.0052-Week Range$4.14▼$10.15Volume8,096 shsAverage Volume19,773 shsMarket Capitalization$249.80 millionP/E RatioN/ADividend YieldN/APrice Target$11.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Nanobiotix alerts: Email Address Nanobiotix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside117.0% Upside$11.50 Price TargetShort InterestHealthy0.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.89) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.96 out of 5 starsMedical Sector779th out of 910 stocksPharmaceutical Preparations Industry363rd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingNanobiotix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNanobiotix has only been the subject of 1 research reports in the past 90 days.Read more about Nanobiotix's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.11% of the outstanding shares of Nanobiotix have been sold short.Short Interest Ratio / Days to CoverNanobiotix has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Nanobiotix has recently decreased by 0.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNanobiotix does not currently pay a dividend.Dividend GrowthNanobiotix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NBTX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Nanobiotix this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nanobiotix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.45% of the stock of Nanobiotix is held by insiders.Percentage Held by InstitutionsOnly 38.81% of the stock of Nanobiotix is held by institutions.Read more about Nanobiotix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nanobiotix are expected to grow in the coming year, from ($0.89) to ($0.31) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Nanobiotix Stock (NASDAQ:NBTX)Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Read More NBTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBTX Stock News HeadlinesSeptember 4 at 4:15 PM | globenewswire.comNANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term GrowthSeptember 3, 2024 | globenewswire.comNanobiotix to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 29, 2024 | americanbankingnews.comNanobiotix (NASDAQ:NBTX) Now Covered by Analysts at GuggenheimJune 12, 2024 | globenewswire.comNANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024June 2, 2024 | globenewswire.comNanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 TherapyMay 28, 2024 | globenewswire.comNANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference CallMay 23, 2024 | globenewswire.comNANOBIOTIX to Present at the Jefferies Global Healthcare ConferenceSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.May 22, 2024 | finanznachrichten.deNanobiotix S.A.: Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term GrowthMay 22, 2024 | globenewswire.comNANOBIOTIX Provides First Quarter 2024 Operational and Financial UpdateMay 21, 2024 | globenewswire.comNanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term GrowthMay 15, 2024 | globenewswire.comNANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024May 14, 2024 | globenewswire.comNANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung CancerApril 29, 2024 | seekingalpha.comNanobiotix S.A. (NBTX) Q4 2023 Earnings Call TranscriptApril 26, 2024 | benzinga.comNanobiotix Stock (NASDAQ:NBTX), Earnings Estimates, EPS, and RevenueApril 24, 2024 | globenewswire.comNANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial ResultsApril 17, 2024 | globenewswire.comNANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024See More Headlines Receive NBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NBTX CUSIPN/A CIK1760854 Webwww.nanobiotix.com Phone33-1-40-26-04-70FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$11.50 High Stock Price Target$12.00 Low Stock Price Target$11.00 Potential Upside/Downside+117.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.75 Quick Ratio1.75 Sales & Book Value Annual Sales$30.06 million Price / Sales8.31 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-132.50Miscellaneous Outstanding Shares47,133,000Free Float45,507,000Market Cap$249.80 million OptionableNot Optionable Beta0.27 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Laurent Levy Ph.D. (Age 51)Co-Founder, President of the Executive Board & CEO Comp: $774.87kMr. Bart Van Rhijn (Age 51)CFO & Member of Executive Board Comp: $682.2kMs. Anne-Juliette Hermant M.A. (Age 50)Chief People Officer & Member of Executive Board Comp: $385.23kDr. Louis Kayitalire M.D. (Age 66)Chief Medical Officer Comp: $543.6kMr. Earl J. Bergey Ph.d. (Age 69)Co-Founder Mr. Craig West CFASenior Vice President of Investor RelationsMr. Brandon OwensVP of Strategic Marketing & Corporate CommunicationMr. Patrick Tricoli M.B.A.Pharm.D., Global Head of Business DevelopmentMs. Margaret GalluzziVP & Global Head of Clinical OperationsMr. Ventzislav Vassilev M.D.VP & Global Head of Safety VigilanceMore ExecutivesKey CompetitorsBicycle TherapeuticsNASDAQ:BCYCAnaptysBioNASDAQ:ANABPraxis Precision MedicinesNASDAQ:PRAXEvolusNASDAQ:EOLSPhathom PharmaceuticalsNASDAQ:PHATView All Competitors NBTX Stock Analysis - Frequently Asked Questions How have NBTX shares performed this year? Nanobiotix's stock was trading at $7.28 on January 1st, 2024. Since then, NBTX shares have decreased by 27.2% and is now trading at $5.30. View the best growth stocks for 2024 here. When did Nanobiotix IPO? Nanobiotix (NBTX) raised $95 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont served as the underwriters for the IPO. How do I buy shares of Nanobiotix? Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NBTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
